Mechanisms involved in the potentiation of paclitaxel or 5-FU by the hypoxic cytotoxin NLCQ-1 (NSC 709257) in vitro

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 2161-2170

  Papadopoulou, Maria V ^a   Ji, Xinhai ^a   Bloomer, William D ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

5 fluorouracil; NLCQ 1; Paclitaxel

Indexed keywords

CASPASE 3; CYTOTOXIN; FLUOROURACIL; NSC 709257; PACLITAXEL; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL HYPOXIA; CELL STRAIN V 79; CELL SURVIVAL; CLONOGENIC ASSAY; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; DNA STRAND BREAKAGE; DNA SYNTHESIS INHIBITION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; STATISTICAL ANALYSIS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL HYPOXIA; CRICETINAE; DNA; DNA DAMAGE; DNA REPAIR; DRUG SYNERGISM; FLUOROURACIL; IMIDAZOLES; PACLITAXEL; PROTEIN BIOSYNTHESIS; QUINOLINES; RNA;

EID: 21344451147     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Hall EJ (ed.): Radiobiology for the Radiologist. 4th ed, Philadelphia, PA. Lippincott, 1994.
2. Hockel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects [Review]. J Nat Cancer Inst 93: 266-276, 2001, and references therein.
3. Dorie MJ and Brown JM: Tumor-specific, schedule-dependent interaction between Tirapazamine (SR 4233) and Cisplatin. Cancer Res 53: 4633-4636, 1993.
4. Dorie MJ, Menke D and Brown JM: Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int J Radiat Oncol Biol Pys 28: 145-150, 1994.
5. Siemann DW: Chemosensitization of CCNU in KHT murine tumor cells in vivo and in vitro by the agent RB 6145 and its isomer PD 144872. Radiother Oncol 34: 47-53, 1995.
6. Papadopoulou MV, Ji M and Bloomer WD: THNLA-1 as radio/chemosensitizer of EMT-6 tumors in mice. Br J Cancer 74(Suppl. XXVII): S267-S270, 1996.
7. Papadopoulou MV, Ji M, Rao MK and Bloomer WD: 9-[3-(2-Nitro-1-imidazolyl) propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer. Oncol Res 8: 425-434, 1996.
8. Papadopoulou MV, Ji M, Rao MK and Bloomer WD: 9-[3-(2-Nitro-1-imidazolyl) propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): a novel DNA-affinic bioreductive agent as chemosensitizer. I Oncol Res 9: 249-257, 1997.
9. Dorie MJ and Brown JM: Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 39: 361-366, 1997.
10. Gallagher R, Hughes CM, Murray MM, Friery OP, Patterson LH, Hirst DG and McKeown SR: The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N. Br J Cancer 85: 625-629, 2001.
11. Lee D-J, Trotti A, Spencer S, Rostock R, Fisher C, von Roemeling R, Harvey E and Groves E: Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study. Int J Radiat Oncol Biol Phys 42: 811-815, 1998.
12. Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R and Kris MG: Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 8: 1269-1271, 1997.
13. Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R, Drobins P, Miller W Jr, Meehan L, McKeon A, Devin J, von Roemeling R and Viallet J: Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 16: 3524-3527, 1998.
14. von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J and Treat J: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. J Clin Oncol 18: 1351-1359, 2000.
15. Papadopoulou MV and Bloomer WD: Exploiting hypoxia in solid tumors with DNA-targeted bioreductive drugs. Drugs Future 29(8): 807-819, 2004.
16. Papadopoulou MV and Bloomer WD: NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug [Review] Clin Cancer Res 9: 5714-5720, 2003.
17. Papadopoulou MV, Ji M, Rao MK and Bloomer WD: 4-[3-(2-Nitro-1-imidazolyl) -propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol Res 12: 185-192, 2000.
18. Papadopoulou MV, Ji M, Rao MK and Bloomer WD: Reductive activation of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257). Oncol Res 14: 21-29, 2003.
19. Papadopoulou MV, Ji M, Rao MK and Bloomer WD: 4-[3-(2-Nitro-1-imidazolyl) -propylamino]-7-chloroquinoline hydrochloride (NLCQ-1). A novel bioreductive agent as radiosenitizer in vitro and in vivo. Comparison with tirapazamine. Oncol Res 12: 325-333, 2000.
20. Papadopoulou MV, Bloomer WD and Hollingshead MG: NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts. Anticancer Res 25(3): 1865-1870, 2005.
21. Blumenthal RD, Taylor A, Osorio L, Ochakovskaya R, Raleigh J, Papadopoulou M, Bloomer WD and Goldenberg DM: Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia. Int J Cancer 94: 564-571, 2001.
22. Papadopoulou MV, Ji M and Bloomer WD: NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo. Int J Radiat Oncol Biol Phys 42: 775-779, 1998.
23. Papadopoulou MV, Ji M, Bloomer WD and Hollingshead MG: Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts. J Exp Ther Oncol 2(5): 298-305, 2002.
24. Papadopoulou MV, Ji M, Ji X, Bloomer WD and Hollingshead MG: Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice. Cancer Chem Pharmacol 50: 501-508, 2002.
25. Papadopoulou MV, Ji M, Ji X and Bloomer WD: Synergistic enhancement of the antitumor effect of taxol by the bioreductive compound NLCQ-1, in vivo. Comparison with tirapazamine. Oncol Res 13: 47-54, 2002.
26. Papadopoulou MV, Ji M, Ji X and Bloomer WD: Therapeutic advantage from combining 5-Fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo. Comparison with tirapazamine. Cancer Chem Pharmacol 50: 291-298, 2002.
27. Papadopoulou MV, Ji M and Bloomer WD: Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and Tirapazamine against EMT6 tumors in mice. Cancer Chem Pharmacol 48(2): 160-168, 2001.
28. Zaider M: Concepts for describing the interaction of two agents. Radiat Res 123: 257-262, 1990.
29. Galvin J, Spaeny-Dekking LHA, Wang B, Seth P, Hack CE and Froelich CJ: Apoptosis induced by granzyme B-glycosaminoglycan complexes: Implications for granule-mediated apoptosis in vivo. J Immunol 162: 5345-50, 1999.
30. Olive PL: Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine. Br J Cancer 71: 529-536, 1995.
31. Papadopoulou MV, Ji M, Khan SH and Bloomer WD: Mechanistic studies regarding the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro. Oncol Res 11: 345-357, 1999.
32. Olive PL and Banath JP: Induction and rejoining of radiation-induced DNA single-strand breaks: 'tail moment' as a function of position in the cell cycle. Mutation Res 294: 275-283, 1993.
33. McGuire WP, Rowinsky EK, Rosenshine NB, Grumbine FC, Ettingger DS, Armstrong DK and Donehower RC: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273-279, 1989.
34. Etlinger DS: Overview of paclitaxel (taxol) in advanced lung cancer. Semin Oncol 20: 46-49, 1993.
35. Forastiere AA: Use of paclitaxel (taxol) in squamous cell carcinoma of the head and neck. Semin Oncol 20: 56-60, 1993.
36. Schmoll HJ, Buchele T, Grothey A and Dempke W: Where do we stand with 5-fluorouracil? [Review] Semin Oncol 26: 589-605, 1999.
37. Liebmann JE, Fisher J, Teague D and Cook JA: Sequence dependence of paclitaxel (taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6: 25-31, 1994.
38. Guichard S, Hennebelle I, Bugat R and Canal P: Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55: 667-676, 1998.
39. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ and Milas L: Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88: 1308, 1996.
40. Thomas DM and Zalcberg JR: 5-Fluorouracil: a pharmacological paradigm in the use of cytotoxics. [Review] Clin Experim Pharmacol Physiol 25: 887, 1998.
41. Aota K, Azuma M, Yamashita T, Tamatani T, Motegi K, Ishimaru N, Hayashi Y and Sato M: 5-Fluorouracil induces apoptosis through the suppression of NF-kappa B activity in human salivary gland cancer cells. Biochem Biophys Res Commun 273: 1168-1174, 2000.
42. Denny WA: Prodrug strategies in cancer therapy [Review]. Eur J Med Chem 36: 577-595, 2001.
43. Papadopoulou MV, Xue C and Bloomer WD: The involvement of DNA repair genes in the hypoxia-dependent NLCQ-1 (NSC 709257) toxicity and its synergistic interaction with cisplatin or melphalan. 12th Int Congress of Radiat Res, Brisbane, Australia, 17-22 August, 2003 (Proceedings).
44. Branham MT, Nadin SB, Vargas-Roig LM and Ciocca DR: DNA damage induced by paclitaxel and DNA repair capability of peripheral blood lymphocytes as evaluated by alkaline comet assay. Mutat Res 560: 11-17, 2004.
45. Ollikainen T, Knuuttila A, Suhonen S, Taavitsainen M, Jekunen A, Mattson K and Linnainmaa K: In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four chemotherapeutic agents. Anti-Cancer Drugs 11: 93-99, 2000.
46. Panadero A, Yin MB, Voigt W and Rustum YM: Contrasting patterns of DNA fragmentation induced by thymidylate synthase inhibitors, ZD1694 and AG-331. Oncol Res 7: 73-81, 1995.
47. Houghton JA, Morton CL, Adkins DA and Rahman A: Locus of interaction among 5-fluorouracil, leucovorin and interferon-alpha 2a in colon carcinoma cells. Cancer Res 53: 44243-44250, 1993.
48. Gagandeep S, Novikoff PM, Ott M and Gupta S: Paclitaxel shows cytotoxicity in human hepatocellular carcinoma cell lines. Cancer Let 136: 109-118, 1999.